Evidence map›Paper›PMID 40273409›Full record

ReviewCanadian Urological Association journal = Journal de l'Association des urologues du Canada2025

Optimizing therapy for high-risk biochemically recurrent non-metastatic prostate cancer Current and emerging strategies.

Christian Kollmannsberger, Antonio Finelli, Andrew Loblaw, Tamim Niazi, Frédéric Pouliot, Ricardo A Rendon, Bobby Shayegan, Fred Saad

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Christian KollmannsbergerDepartment of Medical Oncology, BC Cancer Vancouver Center, Division of Medical Oncology, University of British Columbia, Vancouver, BC, Canada.
Antonio FinelliDivision of Urology, Department of Surgery, University Health Network, University of Toronto, Toronto, ON, Canada.
Andrew LoblawDepartment of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada, ON.
Tamim NiaziDepartment of Radiation Oncology, Jewish General Hospital, McGill University, Montreal, QC, Canada.
Frédéric PouliotDivision of Urology, Department of Surgery, CHU de Québec, Université Laval, QC, Canada.
Ricardo A RendonDepartment of Urology, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax NS, Canada.
Bobby ShayeganDivision of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada.
Fred SaadDivision of Urology, Department of Surgery, Urology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is a leading malignancy affecting men globally and in Canada. Biochemical recurrence (BCR), marked by rising prostate-specific antigen (PSA) levels post-curative-intended local treatment, is prevalent in nearly one-third of prostate cancer patients and is associated with increased risk of metastases and mortality. The management of patients with BCR is evolving rapidly, highlighting the need for practical guidance. This review aims to provide guidance to clinicians on the use and subsequent implications of advanced imaging results in patients with BCR. In addition, current management approaches, including salvage therapies post-radical prostatectomy, as well as the integration of androgen deprivation therapy (ADT) plus androgen receptor pathway inhibitors (ARPI), are explored.

Identifiers

PMID40273409
PMCPMC12327887

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.